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Abstract: There is growing interest in the diagnosis of cognitive impairment among children with epilepsy. It is well 
known that status of seizures control has to be carefully investigated because it can be sufficient “per se” to cause progres-
sive mental deterioration conditions. Subclinical electroencephalographic discharges may have subtle effects on cognition, 
learning and sleep patterns, even in the absence of clinical or sub-clinical seizures. In this respect, electroencephalo-
graphic monitoring (long-term and nocturnal recording) and in particular an all night video-polysomnography (V-NPSG) 
record can be crucial to detect the presence of unrecognized seizures and/or an inter-ictal nocturnal EEG discharge   
increasing. Epileptic encephalopathies (EE) are a group of conditions in which the higher cognitive functions are deterio-
rate as a consequence of epileptic activity, which, in fact, consists of frequent seizures and/or florid and prolonged interic-
tal paroxysmal discharges, focal or generalized. AEDs represent the first line in opposing the burden of both, the poor  
seizures control and the poor interictal discharges control, in the cognitive deterioration of EE affected children. Thus,  
to improve the long-term cognitive/behavioural prognosis in these refractory epileptic children, it should be taken into  
account both a good seizures control and a strict sleep control, choosing carefully antiepileptic drugs which are able  
to control not only seizures clinically recognizable but even the EEG discharges onset and its increasing and spreading 
during sleep. Here, we review the efficacy and safety of the newer AEDs that, to date, are used in the treatment of EE in 
infancy and childhood.  
Key words: Epileptic encephalopathy, refractory epilepsy, AED, anticonvulsant therapy, epilepsy of infancy, epilepsy of child-
hood, interictal epileptic discharges, subtle seizures. 
INTRODUCTION 
  The ILAE Task Force on Classification and Terminology 
proposed the term “Epileptic Encephalopathies” (EE) to refer 
to a category of epilepsies in which the ictal and interictal 
epileptiform (clinical and EEG) abnormalities may contrib-
ute to progressive cerebral dysfunction. This category in-
cludes the following: Ohtahara syndrome, West Syndrome, 
Dravet Syndrome, Doose Syndrome, Lennox-Gastaut   
Syndrome, Landau-Kleffner Syndrome and Electrical Status 
Epilepticus during Sleep (ESES) or Continuous Spike-Wave 
during Slow Sleep (CSWS) [1]. Recently, the so-called   
“severe epilepsy with multiple independent spike foci” has 
been added among the EE [2]. However for some entities, 
such as Dravet syndrome, the relationship between seizures 
severity and psycomothor delay has not been clarified.  
  The main features of EEs include: (I) electrographic   
EEG paroxysmal activity that is often aggressive with   
an high “spikes rate” or “paroxysmal discharges density” (II)  
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seizures that are usually multi-form and intractable, (III) 
cognitive, behavioral, and neurological deficits that may be 
relentless, and (IV) sometimes early death [3]. However the 
clinical spectrum of EEs is largely varied depending on the 
age at onset, epileptic acitvity, genetic and enviromental fac-
tors [4]. It include severe forms with cognitive and motor 
deterioration to slight mild form with better course [5]. Sev-
eral reports suggest that in some children, the seizure control 
[6] results in an improvement of developmental outcome [7]. 
In the treatment of EE the first line consists of pharmacol-
ogical intervention [8, 9]. However the response to anticon-
vulsants is often poor despite aggressive and often off-label 
use of a variety of drugs [10]. New AEDs [gabapentine 
(GBP), topiramate (TPM), levetiracetam (LEV), zonisamide 
(ZNS) and rufinamide (RUF)] (Table 1) have given physi-
cians new options for the treatment of patients with epilepsy 
and, in particular, EE affected. However, 25-30% of children 
with epilepsy are still refractory to these wider treatment 
options. Therefore, the development of new AEDs should be 
continued especially those targeting pediatric epilepsies and 
developing brains [11].  
  Currently, beside classical anti-epileptic drugs, some less 
conventional therapies are utilized in the treatment of intrac-
table seizures, as there are ketogenic diet, immunoglobulins, 
steroids and adrenocorticotrophic hormone [12, 13]. 410    Current Neuropharmacology, 2010, Vol. 8, No. 4  Parisi et al. 
Table  1.  Main Drugs used in Epileptic Encephalopathies. MHD: Oxcarbazepine Metabolite
  10-Hydroxycarbazepine;  Im:  
Intramuscularly 
DRUG  Seizure Type  Oral Dose 
(mg/Kg/Day) 
N° of Daily 
Doses 
Therapeutic  
Serum Level  
Side Effects and Toxicity 
Clobazam  -Add-on / wide spectrum  0, 25-1  1-3  nd  Drowsiness, dizziness, constipation,  
dry mouth, tremor. 
Clonazepam  -Add on / wide spectrum  0, 05 - 0, 15  2-3  20 - 80 μg/ml  Fatigue, drowsiness, hypotonia, behavior 
disturbances, salivary, bronchial  
hypersecretion, respiratory depression. 
Felbamate   -Add-on / Lennox-Gastaut 
syndrome 
15 - 45  2-3  25 -100 μg / ml  Somnolence, anorexia, gastric  
discomfort, nervousness, aplastic  
anemia, hepatotoxicity. 
Gabapentin  -Add-on/ focal and secondary 
generalized  
10 - 30   2-3  6-10 μg/ml  Somnolence, headache, tremor,  
nystagmus, fatigue and weight gain, 
rarely beahavioural disorders. 
Lamotrigine  - Add on/ idiopathic general 
- Add on/ focal 
- Add on/ Lennox Gastaut  
syndrome 
1 - 15  2-3  3 -10 μg/ml  Dizziness, diplopia, ataxia, somnolence, 
rash, Stevens-Johnson syndrome,  
Lyell’s syndrome. 
Levetiracetam   -Add-on/ focal  10 - 60  2  5 - 45 μg /ml 
 
Dizziness; irritability; anxiety,  
headache., weakness; nausea;  
psychotic events (rare) 
Nitrazepam  - Monotherapy infantile spasms  0, 25 - 2, 5  2  40 -180 ng/ml  Hypotonia, drowsiness, aspiration,  
pneumonia. 
Oxcarbazepine  -Add on / focal 
- newly diagnosed / focal 
10 - 45  2-3  12-35 ng/ml 
(MHD) 
Somnolence, headache, ataxia,  
vomiting, hyponatriemia, rash. 
Rufinamide  -Add-on / Lennox-Gastaut  
syndrome 
5-45   2  nd  Dizziness, headache, nausea,  
somnolence, double vision,  
fatigue, ataxia, vomiting. 
Stiripentol  -Add on / Dravet’s syndrome  50 - 100  2-3  nd  Drowsiness, loss of appetite. 
Tiagabine  - Add on / focal  0, 5 -2   2-3  20-100 μg/ml 
 
Dizziness, abdominal pain, nervousness, 
difficulty with concentration,  
non convulsive SE. 
Topiramate   -Add-on / generalized  
Tonic clonic 
-Add-on/ focal 
-Add-on /Lennox Gastaut 
-Monotherapy in newly  
diagnosed focal 
1- 12  2-3  4 - 25 μg/ml  Weight loss, paresthesias, emotional 
lability, difficulty concentrating  
and word-finding, hypohidrosis,  
kidney stones. 
Valproate -  Monotherapy 
/generalized  
15-60 2  40-100  μg/L  Hepatic failure, pancreatitis,  
thrombocytopenia, weight gain,  
tremor, menstrual irregularities. 
Vigabatrin -Monotherapy/  infantile spasms 
-monotherapy/newly  
diagnosed, focal 
40-100; 
100-150 for  
infantile spasms 
2  nd  Excitation, drowsiness, weight gain, 
psychosis (rare), visual field defects. 
Zonisamide  - Add on / wide spectrum  2-12  2  27-43 μg/ml  Somnolence, dizziness, ataxia,  
abdominal discomfort, decreased  
spontaneity, rash, hypohidrosis,  
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Table 1. contd…. 
DRUG  Seizure Type  Oral Dose 
(mg/Kg/Day) 
N° of Daily 
Doses 
Therapeutic  
Serum Level  
Side Effects and Toxicity 
ACTH  - Monotherapy/ infantile spasms  1, 5-3 UI/Kg/day 
im for 1-2weeks 
2 --  Hyperglycemia, hypertension, electrolyte 
abnormalities, gastrointestinal  
disturbances, infections 
Prednisone -Monotherapy/  infantile spasms  2mg/Kg/day  2  --  Obesity, infections,  
hypertension, aggression, weight gain. 
Hydrocortisone  -Monotherapy/ infantile spasms  5-20 mg/Kg/day  2  --  Cushing syndrome,  
irritation, sleep problems, weight  
gain, hypertension. 
 
  Here we review the more frequent EE clinical pictures (at 
the onset and during their natural course) and their pharma-
cological treatments, focusing on the more recent data about 
efficacy and safety of the newer AEDs nowdays available. 
OHTAHARA SYNDROME 
  Ohtahara syndrome (OS), also known as Early-infantile 
EE with suppression-bursts (EIEE) was first described by 
Ohtahara  et al. in 1976 as the earliest form of the age-
dependent EE [4]. The syndrome is outwardly characterized 
by early onset (within a few months of life) of tonic spasms 
and partial seizures (with or without clustering), and receives 
its more elaborate name from the severe and continuous   
pattern of burst activity on the electroencephalogram, the   
so-called “suppression burst” (SB) [14]. This EEG pattern  
is characterized by high voltage bursts alternating with   
almost flat suppression phases at an approximately regular 
rate “Fig. (1)”. The peculiar feature of SB in OS is the   
consistent appearance in both waking and sleeping status and 
regular appearance of periodicity [15].  
  OS range widely from 0.2% to 4% of all childhood epi-
leptic patients [6, 16]. The cardinal seizure type is the tonic 
spasm, lasting 1-10 s, which may be isolated or occur in 
clusters. The spasms occur both during waking and sleeping 
states; they may be generalized and symmetrical or lateral-
ized [17]. Daily seizure frequency is very high, ranging from 
10 to 300 spasms in 10 to 20 clusters [18]. In addition to 
tonic spasms, partial motor seizures, hemiconvulsions, or 
generalized tonic seizures can be recorded in about 30% of 
cases [19]. Myoclonic seizures are rather rarely observed 
[20]. Seizures are difficult to control and with rare excep-
tions, patients have profound mental retardation [3].  
  One of the most remarkable characteristics of OS is its 
age dependent evolution: approximately 75% of children 
with Ohtahara syndrome transform into West Syndrome 
(WS) during 3-6 months of age and further from WS to Len-
nox-Gastaut Syndrome (LGS) at 1-3 years of age, in some 
cases [14, 21]. 
  Etiology is heterogeneous but development in neuroi-
maging technique, particularly MRI, disclosed structural 
abnormalities of the brain as the main cause of OS [19]. 
Most cases are associated with bilateral cortical dysplasia 
[22], but other causes have been reported, including focal 
cortical dysplasia, pachigyria, agyria, hemimegalencephaly, 
corpus callosum hypo- or agenesis, dysgeneses of the colli-
coli, and posterior fossa anomalies [2, 23]. Even cryptogenic 
cases may have undetectable microdysgenesis or migration 
disorders which cause progressive atrophy [22]. Even cyto-
chrome oxidase deficiency [24], and non-ketotic hypergly-
cemia [25] have been reported. 
  Specific mutations in the ARX (aristaless-related ho-
meobox) gene at Xp22.13 have been found in male subjects 
with EIEE [26]. Recently, heterozygous mutations in the 
gene encoding syntaxin-binding protein 1 (Stxbp1) (also 
known as MUNC18-1), an evolutionary conserved neuronal 
Sec1/Munc-18 (SM) protein (STXBP1) that is essential in 
synaptic vesicle release in several species, have been identi-
fied in four unrelated individuals with EIEE [27].  
  Seizures are extremely intractable and prognosis is severe 
with psychomotor retardation; there are many early deaths in 
early infancy [2]. Valproate (VPA) (20-30 mg/Kg/day), ben-
zodiazepines (BDZ) [Clobazam (CLB) 0, 25-1mg/Kg/day; 
Clonazepam (CZP) 0, 1-0, 2 mg/Kg/day], adrenocorticotro-
phic hormone (ACTH) (1, 5-3 UI/Kg/day) and steroids ( 
2mg/Kg/day) including liposteroid [28] are often tried, but 
their efficacy is limited [12]. Thyrotropin releasing hormone 
(TRH) or its analog [29] and ketogenic diet [30, 31] have a 
partial effect in some cases. Gamma-globulin treatment (100 
- 400 mg/Kg/day) is reported to have considerable efficacy 
[32, 33]. Recently chloral hydrate therapy (58 mg/kg/day) 
has been revealed successful in some cases of OS [34]. 
ACTH has proven effective in OS and, more interestingly, in 
some cases it was effective after the transition to WS. In re-
lation to the age at ACTH treatment, patients treated before 3 
months of life seem to be less effective. Moreover ACTH 
treatment is worth trying particularly in cryptogenic cases 
and to try again after the transitional stage to WS in those 
without sufficient efficacy during OS stage [4]. In anecdotic 
cases CZP and acetazolamide (AZD) were effective in OS 
[94]. Vigabatrin (GVG) (starting dose of 40-50 mg/kg/day 
up to 100-250 mg/kg/day) [4] and ZNS ( at doses ranging 
from 2 to over 12 mg/Kg/day) [2, 35] have been reported to 
be of some value. The efficacy of ZNS is observed in some 
cases with complete seizure suppression [2, 35]. ZNS is re-
ported to be effective for partial seizures and for various 
types of seizure disorders, including infantile spasms (IS) 
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leptic profile may be mediated by an effect on the voltage-
sensitive Na
+ channels [35] or on the voltage-dependent T-
type calcium current [37].  
  Clinical and EEG features of OS can be secondary to 
inborn errors of vitamin metabolism such as pyridoxine-
dependent seizures (PDS), folinic acid-responsive seizures, 
and pyridoxal phosphate- dependent seizures. It has become 
good clinical practice to test for pyridoxine (100 mg i.v. in a 
single dose, to be repeated and possibly increased to 500 mg 
in total), folinic acid (3-5 mg/kg per day for two to three 
days) and PLP (30 mg/kg/day in three doses for at least one 
day) dependency in every neonate and infant with ‘difficult-
to treat seizures’ [38]. 
  Surgical interventions demonstrated successful in   
selected infants with brain abnormalities (e.g., megalen-
cephaly) has provided promising results [39, 40]. 
WEST SYNDROME AND INFANTILE SPASMS 
  One of the most known epileptic syndrome is the West 
syndrome (WS), also called Infantile Spasms (IS) or Salaam 
Spams/Tics. Its incidence is estimated about 0, 16-0, 42 per 
1000 live births [4]. In the first description, it was character-
ized by a famous triad that consists of seizures (IS), charac-
teristic abnormalities to the electroencephalography (hypsar-
rhytmia) and psychomotor retardation. The causes of this 
syndrome are heterogeneous and it can be divided in three 
principal group: symptomatic, cryptogenetic and idiopathic. 
In the symptomatic group the epileptic desease is associated 
with various brain damage due to prenatal, perinatal and 
postnatal causes. Cryptogenetic and idiopathic forms remain 
of unknown origin in the majority of the cases. In patients 
who does not meet all the triad criteria’s findings for WS 
(spasms, hypsarrhytmia and psychomotor delay) the term 
“infantile spasm” (IS) is preferred [41]. 
  WS occurs in the first year of life, with a peak age at 5 
months [42]. Seizures are heterogeneous and generally con-
sist of sudden bilaterally and symmetrical spasms of the 
neck, trunk and extremities (flexor, extensor or mixed type), 
with loss of consciousness lasting few seconds or minutes. 
Usually spasms occur in clusters (from 20 at 100 spasm). In 
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many infants the seizures occur at awakening and during 
crying [42]. This form of epilepsy is usually refractory; 
that’s why its prognosis is so poor. Early treatment at the 
onset, decreases the probability of negative prognosis or 
LGS later onset [41, 42].  
  Peculiar EEG findings are fundamental for WS diagno-
sis. In 1950 Gastaut and co-workers described the EEG fea-
tures associated with WS and then Gibbs and others conied 
the term hypsarrhythmia to define an EEG characterized by 
“random high voltage slow waves and spikes, that vary form 
moment to moment in duration and in location: at the onset, 
they appear to be focal and then they seem to originate from 
multiple foci; in few cases the spike discharge becomes gen-
eralized” [43]. The third typical feature is the presence of 
psychomotor retardation. Early start of the therapy with spe-
cific anticonvulsant drugs is very important to control the 
seizures and to improve the outcome [44]. In 1958 Sorel and 
Dusaucy-Bauloye reported that adrenocorticotropic hormone 
(ACTH) controlled the spasms in a number of cases. After 
this discovery, various studies reported the efficacy of 
ACTH and other agents appeared. ACTH and corticosteroids 
would be efficacy due to suppress CRH synthesis. High level 
of CRH during the developmental stage in these patients 
would produce epileptogenic alterations in brainstem [45]. 
The optimum treatment for IS has yet to be proven with con-
fidence, in part because of the different objectives of pub-
lished studies [46].  
  Many new therapeutic options have been tried: GVG, 
ZNS, Nitrazepam (NZP), Methisergide, LEV, TPM, Lamo-
trigine (LTG), Pyridoxine, Ketogenic diet, immunoglobulin 
therapy, felbamate (FLB), and thyrotropin-releasing hor-
mone [47, 48]. ACTH is generally estimated to be more ef-
fective than corticosteroids and it appears to positively alter 
long-term prognosis in the criptogenetic cases more than in 
the symptomatic ones [18]. A common schedule includes 
ACTH, 20 U/day intramuscularly (IM) for two weeks and if 
no response occurs, the dosage is increased to 30 and then 40 
U/day IM for an additional four weeks, then ACTH is re-
placed with oral prednisone ( 2mg/Kg/day for two weeks). If 
the seizure persist, prednisone is given for un additional four 
weeks. The side effects of ACTH include hyperglycemia, 
hypertension, electrolyte abnormalities, gastrointestinal dis-
turbances, infections ( including Pneumocystic carinii pneu-
monia) and transient brain shrinkage observed by CT scan-
ning [50]. GVG has been considered the drugs of first choice 
for patients affected by IS associated with tuberous sclerosis 
and may also be a second-line agent for the treatment of 
other symptomatic IS. The efficacy of GVG is increased 
with high doses (100-150 mg/Kg/day) compared with the 
standard doses (40-100 mg/Kg/day) [50]. Unfortunately, 
rethinopathy GVG-related represents a limit for its use [51, 
52]. Brief period and low dose to minimize the probability of 
visual field defect GVG related has been suggested [14]. In 
case of lack of improvement, GVG should be discontinued 
after 12 weeks [53]. GVG represents the only real achieve-
ment in the effective treatment of IS associated with Tuber-
ous Sclerosis as well as with Focal Cortical Dysplasia (FCD) 
or Down Syndrome. In FCD, GVG treatment seems to be 
able to prevent diffusion of the paroxysmal activity outside 
of the dysplasia [14]. Pyridoxine has been reported to be 
efficacy for IS in Japanese patients, but there are no random-
ized controlled trials in literature [41]. ZNS, intravenous 
immunoglobulin, liposteroid, ketogenic diet, TRH, TPM, all 
have been administered for the treatment of IS, but there are 
insufficient data to determine whether these drugs or combi-
nation therapies are effective or not [43]. 
  To date, ACTH and GVG are considered the most effi-
cacy antiepileptic treatment for WS and IS. However for the 
potential risk of more severe adverse effects with ACTH, 
many clinicians in Canada prefer GVG as first line [54, 55]. 
There are no data on the long-term benefits of different 
therapies in WS and IS both, on seizure control and neuro-
psychological development.  
SEVERE MYOCLONIC EPILEPSY OF INFANCY 
(SMEI) OR DRAVET SYNDROME 
  Severe myoclonic epilepsy of infancy (SMEI; OMIM 
607208) was first described in 1982 by Dravet C et al. [56] 
and recognized as a specific syndrome in 1989 [57]. The 
term Dravet Syndrome (DS) was proposed in 2001 [58]. 
SMEI is an intractable epilepsy of infancy appearing during 
the first year of life in previously healthy children; generally 
the febrile seizures are the first clinical manifestations at 
around 6 months of age (often as “febrile status epilepti-
cus”), followed later by afebrile seizures, often clonic and 
unilateral, of long duration and frequent status epilepticus; 
between 1 and 4 years of age other seizures can be observed 
such as myoclonic jerks, focal seizures and atypical absence 
[59, 60]. The seizures can be triggered by fever or warm 
water [59]. Development is normal in the first year of life, 
with a slowing of psychomotor development, starting in the 
second year of life, that flows into a severe mental retarda-
tion before the age of six years [60]. Ataxia, pyramidal signs 
and interictal myoclonus can occur; the seizures are drug-
resistant, persisting into adulthood [59, 60]. Patients with 
similar clinical features of SMEI, but with not all the diag-
nostic guidelines complete, belong to a subgroup called Bor-
derline SMEI (SMEB) [61, 62]. The EEG is normal in the 
first twelve months, then generalized spike and spike-waves 
complexes at multiple foci appear; photosensitivity can be 
observed in almost the half of patients [60]. Unexpected 
EEG in DS was recently described [63]. 
  The neuroradiological studies are normal in the most of 
patients [64], although different brain abnormalities can oc-
cur [65]; differently, genetic factors play an important role: a 
familial history of febrile seizures or epilepsy is present in up 
to 64% of SMEI patients, and mutations of SCN1A (alpha-1 
subunit of sodium channel) gene are considered responsible 
[60]. The numerous groups which described SCN1A muta-
tions (truncations, splice site, deletion, missense mutations) 
in SMEI patients, report a frequency oscillating from 33 to 
100% of cases and depending from the methods used for 
screening and diagnosis [65-70]; the real estimated percent-
age of mutations in classical SMEI patients is 80% [59]. 
Moreover the coexistence, in SMEI patients, of a family his-
tory of seizure disorders belonging to the Generalized Epi-
lepsy with Febrile Seizures plus (GEFS+) spectrum, and the 
high percentage (95%) of de novo SCN1A mutations, sug-
gested the concept that SMEI is the most severe clinical pic-414    Current Neuropharmacology, 2010, Vol. 8, No. 4  Parisi et al. 
ture of GEFS+ phenotypes [59]. Recently it was established 
that de novo mutations have mainly a paternal origin [71]. 
Additionally, GABRG2 gene has been found as responsible 
for DS in two cases [59], and PCDH19 gene has been related 
to SMEI SCN1A negative patients [72].  
  An early diagnosis of DS or SMEI is important to start a 
treatment that could be able to reduce the number of seizures 
and, mainly, to prevent the episodes of status epilepticus, in 
order to improve developmental outcome; in fact it is well 
know that the developmental delay is related to the onset and 
the frequency of status epilepticus [62]. Moreover, a well-
timed treatment could reduce the risk of sudden death, higher 
in SMEI than other epilepsies (15% versus 5%) [73].  
  VPA, phenobarbital (PB) and BDZ [CPZ, lorazepam 
(LPZ)] are the most useful drugs in DS, by means of a reduc-
tion of the frequency and duration of the seizures [74]; etho-
suximide (ESM) and high doses of piracetam can decrease 
myoclonic seizures [74]. Several case reports of improve-
ment with bromide, corticosteroids, immunoglobulins, 
phenytoin (PTH) are reported [74]. Also various studies have 
suggested the efficacy, rated according to seizure type and 
frequency, of several AEDs added to these baseline drugs; 
among these TPM (starting dose of 0.5-1 mg/kg/day, fol-
lowed by a 2-week titration at increments of 1-3 mg/kg/day 
up to a maximum daily dose of 12 mg/kg) [75] and LEV 
(starting dose of 10 mg/kg/day up to 50 to 60 mg/kg/day in 
two doses) [76].  
  In addition, a CYP450 inhibitor, stiripentol (STP), is con-
sidered effective in patients with SMEI if associated with 
VPA and BDZ, by means of an increase of their plasma con-
centrations and a decrease of their metabolities [77, 78]. 
Also, STP seems to increase the GABAergic transmission, 
suggesting antiepileptic properties “per se” [78]. The advised 
dose of STP is 50 mg/kg/day with a maximum of 3500 
mg/day, 2 or 3 times a day, preferably during meals [78]. It 
is important to notice that specific antiepileptic drugs, such 
as LTG and carbamazepine (CBZ), may exacerbate myoclo-
nic seizures in Dravet Syndrome [62]. The utility of keto-
genic diet in SMEI patients has been showed by a seizures 
reduction [79, 80]. Medications which act mainly as sodium 
channels blockers (LTG, CBZ, PTH) should not be used 
anymore: the SCN1A gain or loss of function observed in 
SMEI is available explanation of the inefficiency of these 
drugs [81]. More recently it has been reported the possible 
role of a voltage-gated calcium channel blocker (Vg-CCB), 
verapamil (VRP), as an add-on anticonvulsant medication in 
Dravet Syndrome [82]. 
DOOSE SYNDROME (MYOCLONIC-ATONIC   
EPILEPSY) 
  The term myoclonic-atonic (or astatic) epilepsy (MAE) 
was used to describe a primary generalized epilepsy of 
childhood characterized by myoclonic and/or astatic seizures 
as main clinical manifestations [83, 84].  
  Initially this term was applied by Doose to a large sub-
group of idiophatic epilepsies with atonic and myoclonic 
seizures. After the ILAE Classification of epileptic syn-
dromes [57], MAE was included in the “cryptogenetic and 
symptomatic epilepsy syndromes”, and then, subsequently, 
in the group of generalized epilepsy [58]. It onsets between 7 
months and 8 years of age (peak between 1 and 5 years; boys 
more affected than girls) with seizures and previous normal 
development. A quick evolution towards generalized jerks 
and astatic falls, which can appear numerous times daily, is 
usually observed. Febrile seizures are observed in one-third 
of cases [59]. Myoclonic-astatic seizures are described as 
brief massive or axial symmetric jerk of neck, shoulders, 
arms and legs, lasting 2-3 seconds, that, if intense and asso-
ciated with a sudden loss of muscle tone, can cause a fall 
[49]. Drops attack and falls, present in about 2/3 of the pa-
tients [85], are responsible for head and face trauma. Other 
types of seizures can occur such as generalized tonic-clonic 
and atypical absence [86]. The children can show also non-
convulsive status, presenting as blurring of consciousness 
associated with ataxia or hypertonus, and face and distal 
muscles contractions; these episodes can arise slowly and 
persist for hours, days or weeks [86]. The ictal EEG shows 
spike waves and poli-spike waves complexes at a frequency 
of 2-4 Hz, while the interictal EEG could be initially normal; 
later, discharges of spike-waves at 3 Hz appear, particularly 
during sleep [86]. A rhythmic theta activity at 4-7 Hz in pa-
rietal and occipital regions and blocked by eye opening is 
frequent [85, 87]. Photosensitivity is not unusual [86]. The 
ictal EEG of non-convulsive status shows irregular slow 
waves and spike-waves complexes [86]. 
  The outcome of MAE at diagnosis is unpredictable; some 
children may develop a severe course with a drug-resistant 
epilepsy, while others, with frequent and severe attacks, may 
have their seizures resolved after a period of 3 years ap-
proximately [85]. The cognitive outcome depends mainly on 
the clinical pattern [88, 89]. The number, frequency and type 
of seizures (falls, atypical absence, GTC, non-convulsive 
status) have been associated with a poor mental outcome [83, 
85]. The neuropsychological findings suggest that electro-
clinical abnormalities can temporarily affect cognitive and 
behavioral functioning. Early effective AEDs could improve 
cognitive outcome [88], as usually happens in the most of 
intractable childhood epilepsy. 
  Neuroradiological studies are generally normal [86]. The 
genetic basis of MAE are unclear. The presence of a com-
plex inheritance was suggested by previous studies on family 
members of MAE patients [83, 84]. In addition mutations of 
sodium channel subunit genes (SCN1A and SCN1B) and of 
GABAa receptor subunit gene (GABRG2) have been found 
in patients with myoclonic-astatic epilepsy belonging to 
GEFS+ family, suggesting the hypothesis that MAE could 
belong to the GEFS+ spectrum [107], while study of spo-
radic cases did not report any mutations [68].  
  AEDs used in MAE are primarily VPA and ESM [85, 
87]. In particular the association between VPA and ESM can 
be advantageous expecially against myoclonic seizures; the 
individual doses are generally regular, although some chil-
dren need of higher doses [90]. BDZ as CZP are helpful, 
although its use is limited by effects on the behavior [86]. 
LTG can be used to control generalized seizures in MAE 
[87, 91]. The use of CBZ and GVG is not recommended 
because they can raise myoclonic attacks as in others myo-
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TPM, LEV, AZD, ESM and sulhtiame (SLT) has been re-
ported by anedoctal case reports [86, 89, 92, 93]. Some stud-
ies have reported the role of the ketogenic diet in patients 
with myoclonic-atonic epilepsy [85, 87, 94], by means of 
both a reduction in seizures and even a complete seizure con-
trol; it should be used early especially in drug resistant cases 
[87, 94]. 
LENNOX-GASTAUT SYNDROME 
  LGS is a rare epileptic encephalopathy described for the 
first time in 1960 by Lennox and his colleagues as a triad of 
symptoms comprising generalized slow spikes-waves 
(SSW), mental deficiency and early onset of multiple and 
different seizures types [95, 96]. 
  As regards the etiology it is usually divided into symp-
tomatic or criptogenetic group, based on the presence or ab-
sence of neurological abnormalities or specific causes. The 
most frequent type is the criptogenetic form. Symptomatic 
cases present different causes such as hypoxic-ischemic en-
cephalopathy, vascular demage, perinatal meningoencepha-
litides, tuberous sclerosis, Down’s Syndrome, trauma, brain 
tumor and malformations [95]; in the 10-25 % of the patients 
a previous history of WS is reported [97]. 
  Clinically the type of seizures are different depending on 
the phases of the syndrome; tonic seizures are the most fre-
quent and peculiar type of seizures (tonic axial seizures, par-
ticularly during sleep), but are not necessarily present at the 
onset. Tonic refers to “a sustained increase in muscle con-
traction lasting a few seconds or minutes”. The patients can 
present flexor movement of head and trunk with apnoea and 
brief cry associated with abduction of the limbs, which usu-
ally involves the arms; in others patients the tonic seizures 
might involve most muscle (global tonic attacks) [98]. The 
second seizure mainly associated with LGS is atypical ab-
sence, characterized by a brief loss of consciousness. Atonic 
falls or drop attacks are hazardous and occur in 56% of pa-
tients who have slow spike-waves, but are not diagnostic of 
LGS [99]. 
  Usually the onset of LGS is about 8 years of age and oc-
currence rates peak between 3 and 5 years. The first manifes-
tation, especially in cryptogenetic form, is a drop attack, fol-
lowed by other type of seizures; EEG abnormalities are not 
yet present and psychomotor/behavioral development at the 
time of first seizure seems normal. Later several seizures 
types occur as tonic, atonic, atypical absence, myoclonic, 
partial or generalized tonic-clonic seizures. At EEG the char-
acteristic and peculiar abnormalities are burst of diffuse slow 
spike-waves at 2-2, 5 c/s during wakefulness, or burst or fast 
waves and slow polyspikes and generalized fast activity at 
about 10 c/s during sleep; this latter EEG finding is almost 
pathognomonic for LGS. Developmental delay increases 
with time and the patients lose cognitive and intellectual 
skills. The prognosis of these patients is very poor and often 
their epilepsy remains untreatable [97]. 
  Old antiepileptic drugs for LGS treatment include BDZ 
[CLB, CZP, diazepam (DZP), LZP, NZP), PB, Primidone 
(PRM), PTH, VPA, GVG [98]. BZD are still prescribed   
with the specific risk in LGS of precipitating tonic status 
epileptic (TSE) [100]. Though they can control tonic-clonic 
seizures, PB and PRM should be avoided due to cognitive 
and sedative side effects [101]. PTH can control tonic-clonic 
seizures and reduce tonic seizures in LGS, but it can aggra-
vate atypical absences and myoclonic seizures [96]. More 
recent therapeutic options in LGS are FBM, LTG, TPM and 
RUF [91, 102]. FBM was the first to be approved for adjunc-
tive therapy in LGS and showed a significant effect on   
“major” seizures. Severe adverse effects appeared a few 
months after approval and so, since 1994, FBM was admin-
istered exclusively for LGS refractory to other AEDs. In the 
last studies it was demonstrated that the risk/benefit of FBM 
therapy supports its use as an important add-on option for 
patients with severe refractory epilepsies [103]. 
  Recent data have demonstrated efficacy of LTG against 
focal seizures, tonic-clonic seizures, tonic seizures, absence 
seizures and atonic seizures [104]. This drug is efficacy es-
pecially in major seizures, but worsening or no improvement 
of myoclonic jerks has been reported. If patients LGS af-
fected are already being treated with an enzyme-inducing 
AED, addition of LTG has to introduce slowly and with cau-
tion. TPM showed efficacy in drop attacks associated with 
LGS in open and double bind randomized study confirming 
the efficacy of TPM in reducing the frequency of atonic sei-
zures with improvement of quality of life [105]. 
  RUF is a new AED that shows good tolerability and effi-
cacy in reducing tonic and atonic seizures, associated with 
LGS [106, 107]. RUF is a triazole derivative and its mecha-
nism of action is an inibition/modulation of NA
+-dependent 
action potentials in neurons and inhibitory effect of the 
GluR5 subtypes at high concentrations. The protective index 
of RUF is higher than that of most common AEDs, like 
PHT, PB, VPA and ESM. Most common adverse events are 
fatigue, vomiting, loss of appetite, headache, somnolence 
and tremor [102]. 
  Antiepileptic and other drugs used “off-label” in LGS are 
AZD, Allopurinol, Bromide, Flunarizine (FNZ), Pyridoxine, 
ZNS [30]. Future AEDs in development for the LGS are 
Carisbamate (CBM), Fluoro-felbamate (FFBM), Ganaxolone 
(GNX) derivates of LEV, Remacemide (RMC), STP, im-
mune treatments, intravenous immunoglobulins, Ketogenic 
and modified Atkins diets [97]. 
  The best treatment for LGS remains uncertain and no 
study to date has shown any one drug to be highly effica-
cious. Until further research has been undertaken, clinicians 
will need to continue to consider each patient individually, 
taking into account the potential benefit of each therapy 
weighed against the risk of adverse effects [102]. 
LANDAU-KLEFFNER SYNDROME 
  Landau Kleffner (LKS) is a rare syndrome of unknown 
etiology, that is more common in the children between 5 and 
7 years af age. It is named for William Landau and Frank 
Kleffner, who in 1957 reported six affected children with 
different type of convulsive seizures and acquired aphasia 
[4]. This functional disorder consists of loss of language 
skills in children previously normal [44]. The regression of 
language may be sudden or prolonged period and aphasia 
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guage disorder can be defined as a verbal auditory agnosia, 
that consists of a loss of verbal comprehension, which may 
be confused as a acquired deafness [108]. The child can be 
unconscious of daily sounds and the hearing is normal, but 
behavioral problems as irritability and poor attention are 
very common. This aphasia is followed by gradual deteriora-
tion also in verbal production and, finally, mutism and fail-
ure to respond to non-verbal sounds [108]. Associated with 
language disorder the children with LKS in the majority of 
cases present different types of seizures, which include epi-
sodes of eye blinking or ocular deviation, head drop and mi-
nor automatisms with secondary generalization. In other 
cases, sizures are focal or toni-clonic generalized seizures, 
typical absences, partial complex ad occasionally myoclonic 
seizures [109].  
  EEG shows bilateral temporal spikes or spikes waves, 
increasing during sleep. In these patients an awake EEG usu-
ally demonstrates normal background activity and focal epi-
leptiform abnormalities especially on the temporal lobes; 
rarely awake EEG can be normal, making video-NPSG man-
datory in these subjects. During the sleep recording EEG it is 
observed an activation and diffusion of the epileptic dis-
charges, whereas the pattern of electrical status epilepticus 
during sleep (ESES or CSWS) may often be observed [108]. 
ESES picture is characterized by a continuous diffuse spike-
waves during SS [36] (see criteria definition for ESES in the 
dedicate paragraph). ESES or CSWS presence is not manda-
tory to make diagnosis of LKS, although it is frequently as-
sociated [110]. 
  Early response to treatment and late outcome in LKS can 
be markedly different if the onset is in pre-linguistic phase 
(onset under the age of 3-4 years) and these children can be 
misdiagnosed for autistic due to impaired linguistic skills 
[111]. 
  Paroxysmal activity of the temporal lobe in LKS children 
reinforces synaptic contacts and it is responsible for perma-
nent language dysfunction. If present, ESES or CSWS is 
able to produce regression of the higher cognitive and execu-
tive functioning [112]. 
  Clinical seizures control in LKS is easy to obtain much 
more than ESES picture remission. Sleep EEG increase dis-
charges in the majority of patients can persist months or 
years causing sometimes severe cognitive impairment, which 
can be transient, fluctuant or, rarely, irreversible with perma-
nent cognitive deficits [108]. 
  Among available AEDs, CBZ may cause a worsening of 
seizures and it should be avoided. The treatment of choice in 
LSK appears to be VPA as mono-therapy or in combination 
with a benzodiazepine [4]. Some authors suggest that ster-
oids and ACTH should be considered the treatment of choice 
especially in early onset of disease in young patient, because 
it seems to have favorable and long-lasting effects, even on 
ESES conditions [113]. The recommended dose of ACTH 
and steroids is high dose for a prolonged period ( 80 UI/d 
with a 3 month taper; prednisone 60 mg/d with a 3 month 
taper) [114]. It was noted that there may be relapses with 
steroids reduction and that some children may need to take 
steroids for months to years. More early the treatment is ini-
tiated and the shorter is the duration for which steroid is re-
quired and better is the outcome.  
  CLB, NZP, VPA, ESM and flunitrazepam have been 
used with benefits. PB, CBZ, PHT have been reported to be 
ineffective or harmful [4]. Patients treated with high-dose 
intravenous corticosteroids succesfully improve in speech 
abilities [114]. Also the successful use of intravenous immu-
noglobulin is known, with both language functions and EEG 
abnormalities influenced significantly by intravenous immu-
noglobulin administration [115]. 
  The prognosis of LKS is benign in most cases, although 
the improvement of language depends on the age of the onset 
(pre and post-linguistic onset) of the disorder and the sever-
ity of the epileptic seizures. Early onset makes the prognosis 
poorer with persistent language difficulties even in the adult 
life [109].  
ESES OR CSWS 
  ESES or CSWS is an EE responsible for less than 1% of 
the age-dependent childhood epilepsies, starting generally 
between the 5
th and 7
th year of life [7]. Even if these two 
terms are considered synonymous, ESES, firstly described 
by Tassinari [116], refers to the EEG pattern (continuous 
spike-wave complexes exclusively during non-REM sleep, 
with a spike-wave index accounting for at least 80-85% of 
SS), while CSWS indicates both EEG features and clinical 
neuropsychological characteristics of this EE [10, 117]. 
From a clinical point of view various seizures type are possi-
ble in CSWS affected patient: generalized tonic-clonic sei-
zures during sleep, atypical absence, myoclonic and atonic 
seizures. Developmental delay and deterioration resulting in 
a IQ reduction, loss of speech, behavior and motor involve-
ment (with ataxia, dystonia, dyspraxia) is often associated [7, 
10]. In CSWS may be present a natural history consisting in 
three phases: initial period with seizures and no developmen-
tal involvement (I); intermediate period with seizures, neu-
ropsychological regression and ESES (II); final period with 
only neuropsychological deficits (III). However this evolu-
tion could be absent, and patients with CSWS/ESES may 
present initially without seizures but “only” with develop-
mental delay and/or behavior disturbance [10]. In these cases 
it could be useful to perform a video-NPSG investigation to 
deeper study the sleep EEG along the entire night. During 
puberty it is possible to observe a remission of seizures, an 
improvement of the behavioral and motor features and a 
normalization of EEG, although EEG anomalies and 
neuropsychological disturbances usually persist [39].  
  A well-known partial epilepsy strongly related to ESES 
or CSWS is the “Atypical Benign Partial Epilepsy of Infancy 
and Childhood” (ABPEI) also known as “Pseudo-Lennox 
Syndrome”, firstly described by Aicard’ e Chevrie [119]. It 
was often mistaken, in the past, for LGS because of the re-
peated atonic falls, absences and slow-wave activity at EEG. 
This form includes generalized seizures, atypical absences 
and atonic-astatic seizures. Axial tonic nocturnal seizures 
frequently observed in LGS are never observed in this type. 
ESES or CSWS can be associated with ABPEI or even, in 
rare cases, with “Rolandic Epilepsy” [119]. Actually, AB-Current Treatment in Epileptic Encephalopathy  Current Neuropharmacology, 2010, Vol. 8, No. 4    417 
PEI, ESES or CSWS and Landau-Kleffner Syndromes are 
four epileptic conditions which clearly overlap and some 
discussion exist about whether they are complication (or 
particular evolution) of rolandic epilepsy, or if they instead 
represent different, although overlapping, epileptic condi-
tions [119]. 
  Numerous antiepileptic drugs have been used for the 
treatment of CSWS, such as LTG, LEV, VPA, steroids, 
BDZ; among the latter, high doses of DZP have been used 
with good results [10]. ESES or CSWS pictures may be 
sometimes particularly refractory to AEDs and corticosteroid 
therapy, in these cases, have shown sometimes good results 
“Fig. (2a and b)”. 
  ACTH or hydrocortisone are effective, but side-effects 
are well-known. High doses of BDZ are effective when 
given in by rapid venous infusion or rectally. However, the 
favorable effects observed after a single administration are 
short-lasting (few hours or days). On the other hand, pro-
longed remissions have been observed after continuous oral 
treatment with BZP (LZP, NZP). The rectal administration 
of DZP 1 mg/kg followed by an oral dose of 0.5 mg/kg/die 
for a period of 3 weeks gave positive results, with remissions 
a 
 
 
 
 
 
 
 
 
 
 
 
 
b 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Before (a) and after (b) oral administration of hydrocortisone for two weeks. Neuropolysomnographic showed both a complete re-
mission of ESES activity and a clear improvement of sleep macrostructure. 418    Current Neuropharmacology, 2010, Vol. 8, No. 4  Parisi et al. 
lasting several months in 9/15 cases of ESES (60%) and in 
one typical case of LKF syndrome [110]. 
SEVERE EPILEPSY WITH MULTIPLE INDEPEND-
ENT SPIKE FOCI 
  The term Severe Epilepsy with Multiple Indipendent 
Spike Foci (SE-MISF) was proposed by Othtahara et al. [22, 
86] as epilepsy with “ three or more indipendent spike foci in 
both emispheres” and “generalized minor seizures”. This 
specific EEG pattern called Multiple Indipendent Spike Foci 
(MISF) had been previously defined by Noriega-Sanchez 
and Markand [120] as a specific electographic finding with 
“more then two independent foci”, related to clinical signs 
and occurring more frequently in children between the age of 
4 and 7 years; the presence of multiple foci may be due to a 
diffuse cerebral pathology, usually involving both the hemi-
spheres. The other peculiarities of SE-MISF are: presence of 
various types of high-frequency generalized minor seizures; 
usual association with mental retardation and neurological 
abnormalities; extensive cerebral pathology linked to non-
specific causes (pre-, peri- and post-natal factors such as 
neurocutaneous diseases, degenerative disease, infections, 
hypoxic ischemic encephalopathy, cerebral malformations, 
hydrocephalus); evolution between the age-dependent epi-
leptic encephalopathy (WS and LGS); extreme seizures in-
tractability [110]. 
  The onset could be between 2 months and 13 years, thus 
indicating that its age-dependency is not identifiable such as 
in the others age-related EE; however, the catastrophic na-
ture of SE-MISF is suggested by the cognitive deficits and 
deterioration observed after the recurrence of refractory sei-
zures, even if it is not easy to establish if it could depends on 
the underlying brain pathology [110]. 
  The treatment of SE-MISF is based on a combination of 
several antiepileptic drugs, such as VPA, BDZ, VGB, PTH, 
ZNS; in addition, only in few selected cases, there is indica-
tion for neurosurgical treatment [110].  
CONCLUSIONS 
  The crucial role potentially acted by interictal electroen-
cephalogram (EEG) discharges [121, 122], even without 
associated seizures [123], in order to cause more or less tran-
sitory cognitive impairment, can play a crucial role in the 
cognitive deterioration associated with EE, particularly in 
children with high rate of interictal spiking and frequent sei-
zures. Cognitive functions, mainly under frontal lobe control, 
seemed to be particularly vulnerable to epileptic EEG activ-
ity during the period of brain development and maturation; 
this age-related disruption possibly interferes with the nor-
mal development of learning processes, showing, sometimes, 
a precise topographic correlation [122, 124-127]. From a 
physiopathological point of view, the most intriguing issue is 
represented by the relationship between ESES and the pat-
tern of neuropsychological and/or motor derangement. Tak-
ing into consideration all above reported data, it become easy 
to understand how important is to look for new AEDs which 
will be able to achieve a better control of both, the seizures 
and interictal paroxysmal EEG abnormalities, particularly 
during sleep [128-130].  
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